Progress in acute myeloid leukemia

Tapan M. Kadia, Farhad Ravandi, Susan O'Brien, Jorge Cortes, Hagop M. Kantarjian

Research output: Contribution to journalReview article

28 Scopus citations


Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age, cytogenetics, and mutational analysis. The following is a comprehensive review of the current state of AML therapy and a roadmap of our approach to these distinct disease entities.

Original languageEnglish (US)
Pages (from-to)139-151
Number of pages13
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number3
StatePublished - Mar 1 2015


  • AML
  • Review
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Progress in acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this

    Kadia, T. M., Ravandi, F., O'Brien, S., Cortes, J., & Kantarjian, H. M. (2015). Progress in acute myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia, 15(3), 139-151.